Editor's note

This ExpertREACT article was originally published on 15 March 2010. Market analysis and pipeline positions described reflect the state of knowledge at that date.

Japanese encephalitis: disease burden and risk

Japanese encephalitis virus (JEV), transmitted by Culex mosquitoes, principally affects children living in rural Asia and parts of the Western Pacific. While accurate figures on disease burden are limited, approximately 35-50,000 people are estimated to contract JE annually with around 10,000 deaths. Critically, 30-50% of cases result in severe neurological sequelae, significantly amplifying the public health burden. Although the risk for travellers to Asia is very low - with only 55 travel-associated cases recorded between 1973 and 2008 - with increased globalisation a growing number of Western travellers remain in JE-endemic areas for extended periods, where their risk approaches that of local residents.

The first new JE vaccine to be licensed in the West was Ixiaro, developed by Vienna-based Intercell AG (licensed from Vaccgen in 2003) and marketed in the US, EU, Japan and Korea by Novartis Vaccines. Ixiaro gained FDA approval on 30 March 2009 and EU approval on 2 April 2009. The product is an inactivated, attenuated JEV vaccine propagated in Vero cells - administered as a two-dose schedule (days 0 and 28) for adults aged 17 years and older. In Australia the vaccine was marketed as JESPECT by CSL Ltd. Ixiaro replaced the previous JE-VAX (mouse-brain derived, distributed by Sanofi Pasteur), which ceased production in Japan and was restricted to US paediatric use pending new-generation vaccine approvals in younger age groups.

JE neurological sequelae rate
30-50%
Of Japanese encephalitis cases result in permanent severe neurological sequelae; estimated 35-50,000 cases and 10,000 deaths annually

Commercial assessment: a nascent market

VacZine Analytics acknowledged that Ixiaro's commercial performance was being closely watched as an early test of Novartis Vaccines' newly established marketing capability - particularly since the company had recently relocated its headquarters from Siena to Boston. The ACIP and JCVI recommendations were positive milestones, but the core traveller market was inherently limited by the low baseline risk of JE in most itineraries. The article suggested it was "too early to call" whether Ixiaro would achieve meaningful commercial traction, noting that pricing, the speed of guideline uptake by travel medicine clinics, and the eventual approval for younger age groups would be decisive in determining the product's longer-term revenue trajectory.